NIKKEI 225
27,782.93 -100.85 (-0.36%) HANG SENG
20,309.13 +116.73 (+0.58%) CRUDE OIL
74.19 +1.22 (+1.67%) GOLD FUTURES
1,999.40 +14.90 (+0.75%) DOW
32,822.11 +104.51 (+0.32%) BTC-GBP
22,562.71 -352.56 (-1.54%)
Moderna, Inc. (MRNA)
| Previous close | 148.80 |
| Open | 150.20 |
| Bid | 147.11 x 1200 |
| Ask | 147.21 x 900 |
| Day's range | 146.60 - 151.25 |
| 52-week range | 115.03 - 217.25 |
| Volume | |
| Avg. volume | 3,606,365 |
| Market cap | 56.413B |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- ACCESSWIRE
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya.
- Business Wire
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn
- ACCESSWIRE
Moderna Finalizes Strategic Partnership with UK Government
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in the UK.
